$IRON

Khara Rahul sold $527K of IRON

Khara Rahul (Chief Legal Officer) sold 7,500 shares of Disc Medicine, Inc. (IRON) at an average of $70.22 ($69.94–$71.62, $0.53M total) across 3 trades on 2026-06-18 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Khara Rahul
Published Jun 23, 2026, 9:21 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 23, 2026, 9:23 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$IRON
Neutral
medium confidence
Mentioned
$IRON
Relevance
4/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$IRONNeutralLow
01

Why it matters

The newest fact is the CLO’s open-market sale details (shares, price range, total value) and that it was executed under a pre-arranged 10b5-1 plan.

02

Market read

Traders may monitor for follow-on insider activity, but the disclosure alone is unlikely to drive a durable repricing without additional company-specific catalysts.

03

What to watch

The article doesn’t state whether the insider’s remaining holdings changed materially beyond the post-transaction share count, nor does it provide context on prior sales or compensation-driven liquidity needs.

Relevance 4/10Novelty 5/10Timing: Form 4 filed after-hours on 2026-06-23; reflects trades dated 2026-06-18.

Background

The article is an SEC Form 4 insider transaction disclosure for Disc Medicine, Inc. (IRON).

Company-level read

Ticker impact

$IRONNeutralMedium confidence
Context

Disc Medicine’s C-suite (Chief Legal Officer) sold 7,500 shares in open-market trades under a pre-arranged 10b5-1 plan, filed June 23.

Expected impact

Likely limited near-term impact; any effect would be sentiment-driven and should fade unless followed by additional disclosures.

Evidence & confidence

The filing is a routine 10b5-1 sale with specified trade dates/prices and no accompanying operational or guidance change in the text.

Market effects

No sector read-through is provided; this is company-specific insider transaction disclosure.

None indicated.

None indicated.

Counterpoint

Because the sale is under a pre-arranged 10b5-1 plan, it may be mechanically scheduled and not a signal of deteriorating fundamentals.

Key entities

  • Disc Medicine, Inc.

    Subject of the Form 4 insider transaction disclosure.

  • Khara Rahul

    Chief Legal Officer who sold shares in open-market trades under a 10b5-1 plan.

Related articles

$IRONMed

Disc Medicine, Inc. (IRON): Results of Operations and Financial Condition

Disc Medicine, Inc. (IRON) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 iron-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Disc Medicine Reports Second Quarter 2026 Financial Results and Provides Business Update • Completed Type A meeting with the FDA on bitopertin and aligned that the Phase 3 APOLLO study, if successful, can serve as the basis f

$NEEMed

SMALL-CAP MOVERS: Britain's bargain basement and the overseas buyers who can't believe their luck

The article reports AIM takeover activity: Gooch & Housego PLC is being acquired in a £346m deal, and Ramsdens Holdings PLC is set to be bought for £230m. It also notes NextEnergy Solar rose 10% after putting itself up for sale, and highlights large AIM share moves for Ironveld, Itaconix, Jersey Oil and Gas, Safestay, Galileo Resources, and Iofina. Iofina reported 393.3 tonnes H1 2026 and raised guidance to 460-485 tonnes.

$IRONMed

Ironveld shares jump 32% at 0.025p as processing plant hits sustained production

Ironveld PLC (AIM:IRON) shares rose 32% to 0.025p after the company said its dense media separation plant reached sustained production. It now runs 16 hours daily on double shift, processing 2.5-3.5 tonnes per hour and producing 1.4 tonnes/hour in-spec magnetite plus about 1 tonne/hour maghemite. Three clients secured, with a 5,000 tonnes/month buyer sampling; expansion options and Mintek study ongoing.

$IRONMed

Disc Medicine Presents Positive Clinical Updates at the 2026 European Hematology Association (EHA) Annual Meeting

Disc Medicine (NASDAQ:IRON) reported updated clinical data at the 2026 EHA meeting in Stockholm. In RALLY-MF, DISC-0974 showed durable overall anemia responses in myelofibrosis across subgroups, including 55% major hemoglobin response in non-transfusion dependent patients and transfusion independence in 64% (TD Low) and 50% (TD High). In HELIOS, bitopertin sustained PPIX reductions and improved light tolerance with favorable longer-term safety. A corporate call is set for June 15.

$IRONLow

Rosen Law Firm Encourages Disc Medicine, Inc. Investors to Inquire About Securities Class Action Investigation - IRON

Rosen Law Firm said it is investigating potential securities claims for Disc Medicine, Inc. (NASDAQ: IRON) shareholders, alleging materially misleading business information. The firm cited an FDA Complete Response Letter on Feb. 13, 2026 for Disc Medicine’s bitopertin NDA, citing uncertainties needing more evidence; IRON shares fell 22% that day.

$IRONLow

Rosen Law Firm Encourages Disc Medicine, Inc. Investors to Inquire About Securities Class Action Investigation - IRON

Rosen Law Firm said it is investigating potential securities claims for Disc Medicine, Inc. (NASDAQ: IRON) investors over allegations of materially misleading business information. The firm cited an FDA Complete Response Letter on Feb. 13, 2026 for Disc Medicine’s bitopertin NDA, citing uncertainties needing more evidence; IRON shares fell 22% that day.